<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Piramal Pharma Limited — News on 6ix</title>
<link>https://6ix.com/company/piramal-pharma-limited</link>
<description>Latest news and press releases for Piramal Pharma Limited on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Tue, 28 Apr 2026 19:51:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/piramal-pharma-limited" rel="self" type="application/rss+xml" />
<item>
<title>Piramal Pharma Limited Announces Results for Q4 and Full-year FY26</title>
<link>https://6ix.com/company/piramal-pharma-limited/news/piramal-pharma-limited-announces-results-for-q4-and-full-year-fy26</link>
<guid isPermaLink="true">https://6ix.com/company/piramal-pharma-limited/news/piramal-pharma-limited-announces-results-for-q4-and-full-year-fy26</guid>
<pubDate>Tue, 28 Apr 2026 19:51:00 GMT</pubDate>
<description>Piramal Pharma Limited (NSE: PPLPHARMA | BSE: 543635), a leading global pharmaceutical, health and wellness company, today announced its standalone and consolidated results for the Fourth Quarter (Q4) and Full-year ended 31st March 2026.</description>
</item>
<item>
<title>Piramal Pharma Solutions and Ajinomoto Bio-Pharma Services Collaborate to Support ADC Development and Manufacturing</title>
<link>https://6ix.com/company/piramal-pharma-limited/news/piramal-pharma-solutions-and-ajinomoto-bio-pharma-services-collaborate-to-support-adc-development-and-manufacturing</link>
<guid isPermaLink="true">https://6ix.com/company/piramal-pharma-limited/news/piramal-pharma-solutions-and-ajinomoto-bio-pharma-services-collaborate-to-support-adc-development-and-manufacturing</guid>
<pubDate>Thu, 16 Apr 2026 12:00:00 GMT</pubDate>
<description>Piramal Pharma Solutions, a leading global Contract Development and Manufacturing Organization (CDMO) and part of Piramal Pharma Ltd. (NSE: PPLPHARMA) (BSE: 543635), and Ajinomoto Bio-Pharma Services ("Aji Bio-Pharma"), a leading provider of biopharmaceutical manufacturing services and platform technologies, have announced a strategic collaboration.</description>
</item>
<item>
<title>Piramal Pharma Solutions Commemorates 20th Anniversary at Morpeth Facility with Procurement of Korsch X3 Tablet Press</title>
<link>https://6ix.com/company/piramal-pharma-limited/news/piramal-pharma-solutions-commemorates-20th-anniversary-at-morpeth-facility-with-procurement-of-korsch-x3-tablet-press</link>
<guid isPermaLink="true">https://6ix.com/company/piramal-pharma-limited/news/piramal-pharma-solutions-commemorates-20th-anniversary-at-morpeth-facility-with-procurement-of-korsch-x3-tablet-press</guid>
<pubDate>Wed, 25 Mar 2026 18:53:00 GMT</pubDate>
<description>Piramal Pharma Solutions, a leading global Contract Development and Manufacturing Organization (CDMO) and part of Piramal Pharma Ltd. (NSE: PPLPHARMA) (BSE: 543635), is proud to announce the installation of a Korsch X3 high containment tablet press at its integrated API and oral solid development and manufacturing site in Morpeth, UK. This acquisition marks a significant milestone as Morpeth celebrates its 20th anniversary, underscoring the facility's expertise and leadership in drug product man</description>
</item>
<item>
<title>Piramal Pharma Solutions' Grangemouth, UK Facility Successfully Delivers 1,500th ADC Batch</title>
<link>https://6ix.com/company/piramal-pharma-limited/news/piramal-pharma-solutions-grangemouth-uk-facility-successfully-delivers-1500th-adc-batch</link>
<guid isPermaLink="true">https://6ix.com/company/piramal-pharma-limited/news/piramal-pharma-solutions-grangemouth-uk-facility-successfully-delivers-1500th-adc-batch</guid>
<pubDate>Mon, 16 Mar 2026 09:26:00 GMT</pubDate>
<description>Piramal Pharma Solutions, a leading global Contract Development and Manufacturing Organization (CDMO) and part of Piramal Pharma Ltd. (NSE: PPLPHARMA) (BSE: 543635), is proud to announce the completion of the 1,500th antibody-drug conjugate (ADC) batch at its dedicated bioconjugate development and manufacturing facility in Grangemouth, UK. With the 1500th batch representing a commercial oncology ADC batch, this milestone highlights the Company's cutting-edge capabilities and unwavering commitmen</description>
</item>
<item>
<title>Press Release Feb 05 2026</title>
<link>https://6ix.com/company/piramal-pharma-limited/news/press-release-feb-05-2026-10</link>
<guid isPermaLink="true">https://6ix.com/company/piramal-pharma-limited/news/press-release-feb-05-2026-10</guid>
<pubDate>Fri, 06 Feb 2026 04:19:02 GMT</pubDate>
<description>Press release dated February 05, 2026, titled Press Release -Collaboration of Piramal Critical Care Inc (PCCI) and Blue-Zone Technologies Ltd (Blue-Zone) to capture, collect and recycle waste anaesthetic gases.</description>
</item>
<item>
<title>Piramal Critical Care and Blue-Zone Technologies collaborate to capture, collect and recycle waste anaesthesia gas</title>
<link>https://6ix.com/company/piramal-pharma-limited/news/piramal-critical-care-and-blue-zone-technologies-collaborate-to-capture-collect-and-recycle-waste-anaesthesia-gas</link>
<guid isPermaLink="true">https://6ix.com/company/piramal-pharma-limited/news/piramal-critical-care-and-blue-zone-technologies-collaborate-to-capture-collect-and-recycle-waste-anaesthesia-gas</guid>
<pubDate>Thu, 05 Feb 2026 17:04:00 GMT</pubDate>
<description>Piramal Critical Care, Inc. (PCC), an overseas subsidiary of Piramal Pharma Limited, and Blue-Zone Technologies Ltd. (Blue-Zone) announced an agreement to collaborate on full lifecycle technology to capture and recycle waste anaesthetic gases.</description>
</item>
<item>
<title>Piramal Pharma Solutions Introduces Tablet-in-Capsule Capabilities</title>
<link>https://6ix.com/company/piramal-pharma-limited/news/piramal-pharma-solutions-introduces-tablet-in-capsule-capabilities</link>
<guid isPermaLink="true">https://6ix.com/company/piramal-pharma-limited/news/piramal-pharma-solutions-introduces-tablet-in-capsule-capabilities</guid>
<pubDate>Mon, 02 Feb 2026 16:00:00 GMT</pubDate>
<description>Piramal Pharma Solutions, a leading global Contract Development and Manufacturing Organization (CDMO) and part of Piramal Pharma Ltd. (NSE: PPLPHARMA | BSE: 543635), is pleased to announce the successful development, scale-up, and commercialization of a tablet-in-capsule drug delivery system at its drug product facilities in Pithampur and Ahmedabad, India. With expanded tablet-in-capsule capabilities now in its toolkit, Piramal can offer partners and patients more flexible and customizable dosin</description>
</item>
<item>
<title>Piramal Pharma Limited Announces Results for Q3 and 9M FY26</title>
<link>https://6ix.com/company/piramal-pharma-limited/news/piramal-pharma-limited-announces-results-053500359</link>
<guid isPermaLink="true">https://6ix.com/company/piramal-pharma-limited/news/piramal-pharma-limited-announces-results-053500359</guid>
<pubDate>Thu, 29 Jan 2026 05:35:00 GMT</pubDate>
<description>Piramal Pharma Limited (NSE: PPLPHARMA) (BSE: 543635), a leading global pharmaceutical, health and wellness company, today announced its standalone and consolidated results for the Third Quarter (Q3) and Nine Month (9M) ended 31st December 2025.</description>
</item>
<item>
<title>Press Release Jan 29 2026</title>
<link>https://6ix.com/company/piramal-pharma-limited/news/press-release-jan-29-2026-6</link>
<guid isPermaLink="true">https://6ix.com/company/piramal-pharma-limited/news/press-release-jan-29-2026-6</guid>
<pubDate>Thu, 29 Jan 2026 05:25:15 GMT</pubDate>
<description>Piramal Pharma Limited has informed the Exchange regarding a press release dated January 28, 2026, titled "Piramal Pharma Limited Announces Results for Q3 and 9M FY26".</description>
</item>
<item>
<title>Piramal Pharma Achieves Notable Score Increase on 2025 S&P Global Corporate Sustainability Assessment (CSA)</title>
<link>https://6ix.com/company/piramal-pharma-limited/news/piramal-pharma-achieves-notable-score-increase-on-2025-sandp-global-corporate-sustainability-assessment-csa</link>
<guid isPermaLink="true">https://6ix.com/company/piramal-pharma-limited/news/piramal-pharma-achieves-notable-score-increase-on-2025-sandp-global-corporate-sustainability-assessment-csa</guid>
<pubDate>Fri, 09 Jan 2026 20:43:00 GMT</pubDate>
<description>PPL proudly announces it has achieved an impressive score of 63 on the 2025 S&P Global CSA. This marks a substantial 15% improvement over last year's score of 55, reflecting the Company's ongoing commitment to sustainability and responsible operations.</description>
</item>
<item>
<title>Piramal Pharma Solutions Demonstrates Commitment to Excellence with Outstanding Net Promoter Score</title>
<link>https://6ix.com/company/piramal-pharma-limited/news/piramal-pharma-solutions-demonstrates-commitment-to-excellence-with-outstanding-net-promoter-score</link>
<guid isPermaLink="true">https://6ix.com/company/piramal-pharma-limited/news/piramal-pharma-solutions-demonstrates-commitment-to-excellence-with-outstanding-net-promoter-score</guid>
<pubDate>Mon, 15 Dec 2025 05:49:00 GMT</pubDate>
<description>Piramal Pharma Solutions, a leading global Contract Development and Manufacturing Organization (CDMO) and part of Piramal Pharma Ltd. (NSE: PPLPHARMA) (BSE: 543635), has achieved an impressive Net Promoter Score (NPS) of 55 for the time period representing FY2025 (April 2024 – March 2025). This serves as a testament to the Company's ongoing dedication to excellence and collaboration.</description>
</item>
<item>
<title>Piramal Pharma Solutions Achieves Regulatory Compliance for Nitrosamine Impurities</title>
<link>https://6ix.com/company/piramal-pharma-limited/news/piramal-pharma-solutions-achieves-regulatory-compliance-for-nitrosamine-impurities</link>
<guid isPermaLink="true">https://6ix.com/company/piramal-pharma-limited/news/piramal-pharma-solutions-achieves-regulatory-compliance-for-nitrosamine-impurities</guid>
<pubDate>Wed, 26 Nov 2025 19:13:00 GMT</pubDate>
<description>Piramal Pharma Solutions, a leading global Contract Development and Manufacturing Organization (CDMO) and part of Piramal Pharma Ltd. (NSE: PPLPHARMA) (BSE: 543635), today announced the successful completion of its journey to compliance with global requirements for nitrosamine impurities in pharmaceuticals.</description>
</item>
<item>
<title>Piramal Pharma Solutions' Bioconjugates Facility in Grangemouth, UK Receives Updated MHRA GMP Certificates</title>
<link>https://6ix.com/company/piramal-pharma-limited/news/piramal-pharma-solutions-bioconjugates-facility-in-grangemouth-uk-receives-updated-mhra-gmp-certificates</link>
<guid isPermaLink="true">https://6ix.com/company/piramal-pharma-limited/news/piramal-pharma-solutions-bioconjugates-facility-in-grangemouth-uk-receives-updated-mhra-gmp-certificates</guid>
<pubDate>Wed, 19 Nov 2025 07:41:00 GMT</pubDate>
<description>Piramal Pharma Solutions, a leading global Contract Development and Manufacturing Organization (CDMO) and part of Piramal Pharma Ltd. (NSE: PPLPHARMA) (BSE: 543635), is pleased to announce that its Grangemouth, UK facility has received updated MHRA GMP certificates following a successful compliance report and desktop inspection.</description>
</item>
<item>
<title>Press Release Nov 05 2025</title>
<link>https://6ix.com/company/piramal-pharma-limited/news/press-release-nov-05-2025-7</link>
<guid isPermaLink="true">https://6ix.com/company/piramal-pharma-limited/news/press-release-nov-05-2025-7</guid>
<pubDate>Thu, 06 Nov 2025 02:03:15 GMT</pubDate>
<description>Piramal Pharma Limited has informed the Exchange regarding a press release dated November 05, 2025, titled "Piramal Pharma Limited Announces Results for Q2 and H1 FY26".</description>
</item>
<item>
<title>Piramal Pharma Limited Announces Results for Q2 and H1 FY26</title>
<link>https://6ix.com/company/piramal-pharma-limited/news/piramal-pharma-limited-announces-results-for-q2-and-h1-fy26</link>
<guid isPermaLink="true">https://6ix.com/company/piramal-pharma-limited/news/piramal-pharma-limited-announces-results-for-q2-and-h1-fy26</guid>
<pubDate>Wed, 05 Nov 2025 17:57:00 GMT</pubDate>
<description>Piramal Pharma Limited (NSE: PPLPHARMA) (BSE: 543635), a leading global pharmaceutical, health and wellness company, today announced its standalone and consolidated results for the Second Quarter (Q2) and Half Year (H1) ended 30th September 2025.</description>
</item>
<item>
<title>Piramal Pharma Solutions Formalizes Partnership with IntoCell, Expanding its Payload-Linker Platform and Bioconjugate Capabilities</title>
<link>https://6ix.com/company/piramal-pharma-limited/news/piramal-pharma-solutions-formalizes-partnership-with-intocell-expanding-its-payload-linker-platform-and-bioconjugate-capabilities</link>
<guid isPermaLink="true">https://6ix.com/company/piramal-pharma-limited/news/piramal-pharma-solutions-formalizes-partnership-with-intocell-expanding-its-payload-linker-platform-and-bioconjugate-capabilities</guid>
<pubDate>Thu, 30 Oct 2025 05:15:00 GMT</pubDate>
<description>Piramal Pharma Solutions, a leading global Contract Development and Manufacturing Organization (CDMO) and part of Piramal Pharma Ltd. (NSE: PPLPHARMA) (BSE: 543635), has signed a Memorandum of Understanding (MOU) to solidify its strategic partnership and explore potential collaboration opportunities in ADC development with IntoCell Inc. (KOSDAQ: 287840), a leading Korean biotechnology company specializing in innovative antibody-drug conjugate (ADC) linker and payload platform technologies. Pursu</description>
</item>
<item>
<title>Piramal Pharma Solutions Augments Formulation Capabilities with the Addition of New Korsch XM-12 Bilayer Tablet Press at its Morpeth, UK Facility</title>
<link>https://6ix.com/company/piramal-pharma-limited/news/piramal-pharma-solutions-augments-formulation-capabilities-with-the-addition-of-new-korsch-xm-12-bilayer-tablet-press-at-its-morpeth-uk-facility</link>
<guid isPermaLink="true">https://6ix.com/company/piramal-pharma-limited/news/piramal-pharma-solutions-augments-formulation-capabilities-with-the-addition-of-new-korsch-xm-12-bilayer-tablet-press-at-its-morpeth-uk-facility</guid>
<pubDate>Tue, 16 Sep 2025 11:25:00 GMT</pubDate>
<description>Piramal Pharma Solutions, a leading global Contract Development and Manufacturing Organization (CDMO) and part of Piramal Pharma Ltd. (NSE: PPLPHARMA) (BSE: 543635), is excited to announce its recent acquisition of a state-of-the-art Korsch XM-12 bilayer tablet press at its drug product facility in Morpeth, UK. The Morpeth facility plays a vital role in the company's integrated offering, providing specialized services for the development and manufacturing of oral solids and hormonal products.</description>
</item>
<item>
<title>Piramal Pharma Solutions Supports George Medicines in Developing its New Drug for Hypertension, WIDAPLIK™ (telmisartan, amlodipine and indapamide)</title>
<link>https://6ix.com/company/piramal-pharma-limited/news/piramal-pharma-solutions-supports-george-medicines-in-developing-its-new-drug-for-hypertension-widapliktm-telmisartan-amlodipine-and-indapamide</link>
<guid isPermaLink="true">https://6ix.com/company/piramal-pharma-limited/news/piramal-pharma-solutions-supports-george-medicines-in-developing-its-new-drug-for-hypertension-widapliktm-telmisartan-amlodipine-and-indapamide</guid>
<pubDate>Thu, 28 Aug 2025 15:58:00 GMT</pubDate>
<description>George Medicines, a leading late-stage biopharma company, in partnership with Piramal Pharma Solutions (PPS), a leading global Contract Development and Manufacturing Organization (CDMO) and part of Piramal Pharma Ltd. (NSE: PPLPHARMA) (BSE: 543635) developed WIDAPLIK, a new drug for treatment of hypertension in adult patients, including as initial treatment, to lower blood pressure. The U.S. Food and Drug Administration (FDA) approved WIDAPLIK on June 6, 2025.</description>
</item>
<item>
<title>Piramal Pharma Publishes FY2025 Sustainability Report, Outlining Performance and Decarbonization Glidepath</title>
<link>https://6ix.com/company/piramal-pharma-limited/news/piramal-pharma-publishes-fy2025-sustainability-report-outlining-performance-and-decarbonization-glidepath</link>
<guid isPermaLink="true">https://6ix.com/company/piramal-pharma-limited/news/piramal-pharma-publishes-fy2025-sustainability-report-outlining-performance-and-decarbonization-glidepath</guid>
<pubDate>Tue, 26 Aug 2025 08:58:00 GMT</pubDate>
<description>Piramal Pharma Limited (PPL) (NSE: PPLPHARMA) (BSE: 543635), a leading global pharmaceuticals company, has released its fourth annual Sustainability Report for the financial year 2025, under the theme 'Innovating Responsibly. Growing Sustainably.' The report outlines measurable progress and strengthened commitments under its four strategic pillars: Business Resilience, Quality & Excellence, Responsible Operations, and Stakeholder Centricity. It underscores PPL's purpose of 'Doing Well and Doing</description>
</item>
<item>
<title>Press Release Aug 21 2025</title>
<link>https://6ix.com/company/piramal-pharma-limited/news/press-release-aug-21-2025-6</link>
<guid isPermaLink="true">https://6ix.com/company/piramal-pharma-limited/news/press-release-aug-21-2025-6</guid>
<pubDate>Thu, 21 Aug 2025 21:00:30 GMT</pubDate>
<description>Press Release - Piramal Pharma Solutions ("PPS") and NewAmsterdam Pharma invest indedicated suite to enhance Oral Solid Dosage capabilities at PPS' Sellersville, Pennsylvania site</description>
</item>
</channel>
</rss>